Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug
Pays $55m Upfront For Sparsentan
The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.
